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Many targeted drugs have been studied to target the molecular pathways involved in the
development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also
multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic
colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated
with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard
treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been
approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a
great number of further drugs are under preclinical and clinical development. The aim of this
review is to provide a comprehensive overview of the state of art, focusing on the new
emerging strategies in the personalized treatment of gastrointestinal tumors.
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The main pathways involved in
gastrointestinal tumors
VEGF/VEGFR pathway
Tumor-related angiogenesis has a predominant
role in gastrointestinal (GI) cancers. This pro-
cess involves the formation of new blood vessels
within the tumor to provide nutrients and oxy-
gen. VEGF is an endothelial cell-specific mito-
gen that induces angiogenesis and is expressed
in various human tumors [1].
VEGF was first isolated in 1983 as a factor
leading to increased vascular permeability in
tumors. VEGF-A is the most important
member of a family of homodimeric glyco-
proteins. This family of proteins is structur-
ally related to the PDGF; and it also
includes PlGF, VEGF-B, VEGF-C, VEGF-D
and VEGF-E. These growth factors bind
selectively, but with different affinity, to at
least five distinct receptors. In particular,
VEGF-A binds to receptors VEGFR-1 and
VEGFR-2. Preclinical studies in mice showed
that the inactivation of VEGFR-1 and
VEGFR-2 as well as neuropilin-1 induces
impairment of blood vessel formation and
embryonic lethality, supporting the impor-
tant role of VEGF-A for a proper vascular
development [2–4].
Both normal function, including embryogene-
sis, the female reproductive cycle, pregnancy,
wound healing and disease-related phenomena,
such as tumor growth, diabetic retinopathy and
ischemic diseases, are subsequent to the upregu-
lation of the VEGF/VEGFR system [5]. In the
search for the mechanisms and factors able to
regulate VEGF gene expression during these
processes, many cytokines and growth factors
are involved [6]. For example, TNF-a and
bFGF are able to induce VEGF gene expression
in vitro, but also glucose deficiency has this
effect. However, the main factor able to regulate
its expression is hypoxia [7–9]. As a consequence
of hypoxia development, specific hypoxia-
inducible transcription factors, HIF-1 and
HIF-2, are activated and induce VEGF expres-
sion. In addition, VEGF upregulation during
hypoxia is also achieved by an increase in the
stability of its mRNA51 and by the efficient
hypoxic translation of the VEGF mRNA, which
is mediated by an internal ribosomal entry
site [10–12].
In endothelial cells, VEGFR-2 is considered
to be the major signaling receptor, while
VEGFR-1 acts as a sink to trap an excess of
VEGF. Endothelial proliferation is mediated
via the Ras-Raf-MAP kinase pathway, while
protein kinase C activation is involved in
endothelial migration and vascular permeabil-
ity. The role of VEGF as a survival factor for
endothelial cells is mediated by the PI3K-AKT
signaling pathway [13].
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EGFR/HER2 pathway
The family of ErbB receptors includes four homologous
receptors: the EGFR (ErbB1/EGFR/HER1), ErbB2 (HER2/
neu), ErbB3 (HER3) and ErbB4 (HER4) [14]. The EGFR
is a membrane-bound tyrosine kinase that contributes to
signaling cascades with multiple procarcinogenic effects
including cell proliferation, motility, adhesion, invasion, cell
survival and angiogenesis.
EGFR overexpression has been detected in several human
cancers, including colorectal cancer, and it is related to progres-
sion and metastasis. HER2 overexpression or gene amplification
has been observed in multiple malignancies, including gastric
cancer. These receptors are composed of an extracellular bind-
ing domain, a transmembrane lipophilic segment and an intra-
cellular protein TK domain. A cross-talk between the various
ErbB receptors has been already known. It regulates the cellular
effects mediated by these receptors [15].
At least six different ligands, known as EGF-like ligands, can
bind to EGFR. These ligands include EGF, TGF-a, amphire-
gulin, heparin-binding EGF, betacellulin and epiregulin. A sec-
ond class of ligands, collectively termed heregulins, binds
directly to HER3 and/or HER4.
After their binding to ErbB receptors these are activated by the
dimerization between two identical receptors (homodimerization)
or between different receptors of the same family (heterodimeriza-
tion). This dimerization allows tyrosine autophosphorylation and
subsequently the recruitment and phosphorylation of several
intracellular proteins, which mainly belong to the Ras-Raf-MAPK
and the PI3K-Akt pathways. RAS protein function is normally
regulated by cycling between inactive GDP-bound and active
GTP-bound forms. Signaling is terminated when RAS-GTP is
hydrolyzed to the RAS-GDP inactive complex by GTPase-
activating proteins. Activated RAS recruits Raf protein to the cell
membrane and phosphorylates it, triggering serine-threonine
kinase activity of various proteins [16]. Finally, active MAPKs can
translocate to the nucleus, where they regulate the activity of sev-
eral transcription factors for the expression of multiple genes of
survival and proliferation [17].
PTEN-PI3K-AKT-mTOR pathway
PI3Ks are a family of lipid kinases that phosphorylate the
3´-hydroxyl group of phosphoinositides with conversion of phos-
phatidylinositol-4,5-biphosphate (PIP2) to phosphatidylinositol-
3,4,5-trisphosphate (PIP3). PIP3 is a critical second messenger
that activates AKT (also known as protein kinase B) through
phosphorylation. Once activated, phospho-AKT phosphorylates
up to 100 other proteins, including the mTOR. mTOR com-
plexes with regulatory associated protein of mTOR and
rapamycin-insensitive companion of mTOR to form mTOR
complex 1 (mTORC1) and mTORC2, respectively [18,19].
US FDA-approved targeted drugs
Nowadays, targeted drugs have been developed with the perspec-
tive of sparing cancer patients from chemotherapy-related toxic-
ity. However, some of these agents showed their best efficacy in
combination with chemotherapy regimens. A lot of new targeted
drugs are still under development, but monoclonal antibodies
and small molecule inhibitors are actually available after the US
FDA approval to treat GI cancers (TABLE 1). These agents are able
to target VEGF/VEGFR or EGFR/HER2 pathways.
Colorectal cancer
Recently, the combination of targeted drugs and irinotecan/
oxaliplatin-based chemotherapy regimens has improved the effi-
cacy of standard treatment for colorectal cancer patients.
Bevacizumab is a humanized monoclonal antibody (mAb),
Table 1. Approved targeted agents in advanced gastrointestinal tumors.
Type of tumor Targets Drugs Setting Overall survival Ref.
Colorectal cancer VEGF Bevacizumab First-line,
Second-line
Beyond PD
21.3 months
12.9 months
11.2 months
[21,29,31]
Aflibercept Second-line 13.5 months [32]
EGFR Cetuximab First-line (KRAS-wild-type) 23.5 months [23]
Panitumumab First-line (RAS-wild-type),
second-line (KRAS-wild-type)
26.0 months
14.5 months
[24,33]
VEGFR, BRAF,
KIT, RET, PDGFR
Regorafenib Third-line 6.4 months [34]
Gastric cancer HER2 Herceptin First-line 13.8 months [38]
Hepatocellular carcinoma VEGFR, BRAF,
KIT, RET, PDGFR
Sorafenib First-line 10.7 months
6.5 months
[39,40]
Neuroendocrine
gastroenteropancreatic
tumors
VEGFR, BRAF,
KIT, RET, PDGFR
Sunitinib Second-line N.A [45]
mTOR Everolimus Second-line N.A [46]
N.A: Not available.
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which inhibits angiogenesis by its binding to VEGF. Various
Phase III trials evaluated patients with previously untreated
metastatic colorectal cancer (mCRC) who were randomly
assigned to receive irinotecan, bolus fluorouracil and leucovorin
(IFL) plus bevacizumab or IFL plus placebo. In this pivotal
trial, the median duration of survival was 20.3 months in the
group receiving IFL plus bevacizumab versus 15.6 months in
the control group. These results were quite impressive [20].
Other trials have failed to demonstrate the same statistically sig-
nificant results in survival, particularly with other backbone
regimens, such as isolated capecitabine or oxaliplatin-containing
regimens like FOLFOX or XELOX plus placebo or bevacizu-
mab in first-line mCRC (median overall survival [mOS]
19.9 vs 21.3 months in bevacizumab group) [21]. Cetuximab
and panitumumab are anti-EGFR mAbs delivered alone or in
combination with chemotherapy. To date, the main factor con-
ditioning their use is KRAS and NRAS mutation status. Even
BRAF mutation seems to have a role as a predictive factor for
the efficacy to anti-EGFR mAbs, but its prognostic role appears
predominant. After the detection of somatic RAS gene muta-
tions, each oncologist is able to know if a mCRC patient could
have a benefit from the combination of the anti-EGFR mAbs
with standard chemotherapy doublets [22]. In fact for RAS
wild-type patients, the benefit in OS was observed for both
these two combinations: FOLFIRI + cetuximab, as shown in
the CRYSTAL trial [23] and FOLFOX + panitumumab, as
reported in the PRIME trial after the specific evaluation of
both KRAS and NRAS gene mutations [24]. Some concerns
have been reported in guidelines for the combination of
oxaliplatin-based regimens with cetuximab. It showed no addi-
tional benefit in OS in the OPUS trial and in some studies
more toxicity has been recorded, as reported in NORDIC VII
and COIN trials [25–27]. For this reason, in KRAS or NRAS
mutated mCRC patients, who cannot receive anti-EGFR
mAbs, FOLFOX + bevacizumab represents the best option,
instead of FOLFOX or FOLFIRI alone, because it can delay
progression even though it cannot reduce the risk of death [28].
Nowadays, targeted therapy has also a role for the second-line
treatment. It is mainly influenced by the scant evidences about
a re-challenge with the same chemotherapeutic regimen.
The re-challenge with bevacizumab has been shown to give fur-
ther benefit [29]. For the re-challenge with cetuximab, some
intriguing results have been reported till now, but strong evi-
dences are still not available [30]. For this reason, the more valid
options for second-line treatment are represented by
FOLFOX + bevacizumab for those RAS wild-type patients who
received FOLFIRI + cetuximab as first-line treatment, and
FOLFIRI + aflibercept after first-line treatment with
FOLFOX + panitumumab. The first second-line option is sup-
ported by the results from E3200 trial, which obtained survival
benefit through the addition of bevacizumab to oxaliplatin-
based treatment in those patients who did not receive bevacizu-
mab before [31]. The other one is based on the results of
VELOUR trial, which reported an OS benefit when aflibercept
was added to FOLFIRI after a previous treatment with an
oxaliplatin-based regimen [32]. Aflibercept is a recombinant
fusion protein consisting of VEGF-binding portions from the
extracellular domains of VEGFR-1 and VEGFR-2, which are
fused to the Fc portion of the human IgG1 immunoglobulin.
In RAS mutated mCRC patients who received an oxaliplatin-
based regimen plus bevacizumab as first-line treatment, two
options are available on the basis of evidence-based findings
from Phase III trials with OS benefit. These chances include
both FOLFIRI + aflibercept according to the VELOUR trial’s
results and FOLFIRI + bevacizumab as highlighted by the
ML18147 trial. Both these two combination regimens are
superior to FOLFIRI alone in terms of OS. Moreover,
panitumumab-FOLFIRI represents a valid option for wild-
type KRAS, mCRC patients, who received an oxaliplatin-
based regimen plus bevacizumab as first-line treatment [33].
A further effective option with a targeted drug could be
offered to those patients, who have an acceptable general
health status after the first- and second-line treatments.
Indeed, regorafenib, a BRAF inhibitor, showed an OS benefit
over placebo in the Phase III CORRECT trial for unselected
patients who previously were treated with irinotecan- and
oxaliplatin-based regimens [34]. Recently, FIRE-3 trial, which
compares the combination of chemotherapy and bevacizumab
with the same chemotherapy and cetuximab in KRAS wild-
type mCRC patients, provided interesting results useful for
the decision-making in first-line treatment. Indeed, cetuxi-
mab achieved a better OS compared with bevacizumab with-
out difference in progression-free survival (PFS). These
findings are controversial and should be better clarified with
further studies, since PFS and OS were not the primary end
points in this trial [35].
Gastric cancer
Advanced gastric cancer (aGC) patients obtain an improve-
ment in survival from combination chemotherapy more than
from mono-chemotherapy [36]. About 20% of gastric and
esophagogastric junction tumors overexpress HER2. This
finding provided a rationale to investigate a biological target
therapy as trastuzumab, a mAb directed against the extracel-
lular domain of HER2 protein, also in gastric cancer [37].
ToGA trial was designed to explore the efficacy of trastuzu-
mab. It is an open-label Phase III trial, which investigated
the survival benefit induced by trastuzumab in combination
with chemotherapy for first-line treatment of HER2-positive
advanced gastric or gastroesophageal junction (GEJ) cancer.
Median OS was favorable for trastuzumab plus chemotherapy
arm (13.8 vs 11.1 months), with 26% reduction in the death
rate. Anyway, the benefit of trastuzumab has been shown
only for those patients whose tumors were at immunohis-
tochemistry (IHC) 3+ or IHC 2+ and positive at fluorescence
in situ hybridization, but no survival benefit was found in
IHC 0 or 1+ and positive at FISH [38]. These results
prompted the admission of this combination as a new stan-
dard therapy for patients affected by inoperable/metastatic
gastric or GEJ cancer.
The role of targeted therapy for GI tumors Review
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Hepatocellular carcinoma
Sorafenib is a multikinase inhibitor that blocks tyrosine
kinase activity in membrane receptors, such as VEGFR and
PDGFR, and determines the inhibition of tumor vasculariza-
tion and proliferation. This drug was approved for systemic
treatment of patients with advanced inoperable hepatocellular
carcinoma (HCC), Child–Pugh class C patients. SHARP [39]
and Asia-Pacific trials [40] showed a statistically significant
3 and 2 months improvement of mOS, respectively by sora-
fenib compared with placebo (SHARP: 10.7 vs 7.9 months,
hazard ratio [HR]: 0.69; 95% CI: 0.55–0.87; p < 0.001;
Asia-Pacific: 6.5 vs 4.2 months, HR: 0.68; 95% CI: 0.50–
0.93; p = 0.014). In both these studies, a benefit from sorafe-
nib was also observed for median time to progression (TTP)
(SHARP: 5.5 vs 2.8 months, HR: 0.58; 95% CI: 0.45–0.74;
p < 0.001; Asia-Pacific: 2.8 vs 1.4 months, HR: 0.57; 95%
CI: 0.42–0.79; p = 0.0005). Therefore, sorafenib provides a
good efficacy in terms of TTP and OS with an acceptable
tolerability profile. These results could be translated into an
increase of about 11% for 1-year survival rate and about
31% of death risk reduction. This benefit is also maintained
if these data are adjusted for some prognostic factors by mul-
tivariate analysis, including electrocorticography performance
status, vascular invasion, extrahepatic extension, Child–Pugh
status, a-fetoprotein, serum albumin, alkaline phosphatase
and bilirubin. However, an improvement of response rates
was not observed in these trials. In fact, partial responses
were just 7 out of 299 (2%) in the SHARP trial and just
5 out of 150 patients (3.3%) in the Asia-Pacific trial. No
complete responses were observed. Recently, sorafenib has
also been proposed for use with caution in Child–Pugh class
B patients, in particular if bilirubin levels are elevated [41]. It
is approved for metastatic, unresectable and extensive HCC
without suitability for liver transplantation. Those patients
with local disease could also be treated with sorafenib, if
they are not operable because of worse performance status
or comorbidity.
Neuroendocrine gastroenteropancreatic tumors
Some years ago, the treatment options for neuroendocrine gas-
troenteropancreatic tumors were quite limited. Recently, two
targeted agents, sunitinib and everolimus, achieved antitumor
activity and improvement of PFS. For these reasons, these
two drugs have been approved for the systemic treatment of
these malignancies.
Sunitinib is an oral small-molecule, multi-targeted receptor
tyrosine kinase inhibitor (TKI) for VEGFR and PDGFR. It
plays a role in both tumor angiogenesis and tumor cell prolifer-
ation. The tumor shrinkage induced by the concomitant inhibi-
tion of these two target proteins is mediated by both reduced
tumor vascularization and cancer cell death. Other target pro-
teins have been identified, which include KIT, RET, CSF-1R
and flt3 [42–44]. Sunitinib was studied in comparison with pla-
cebo in a multicenter randomized trial for pretreated patients
with advanced pancreatic neuroendocrine tumors. This trial
showed a PFS of 11.4 months for sunitinib versus 5.5 months
in the control arm (p < 0.001). The difference in OS was not
significant because a large proportion of patients progressing on
placebo received sunitinib as subsequent treatment. The most
frequent side effects of sunitinib include fatigue, diarrhea, nau-
sea, anorexia, hypertension, a yellow skin discoloration, hand-
foot skin reaction and stomatitis [45]. Everolimus is a derivative
of sirolimus, which inhibits the mTOR. As the other mTOR
inhibitors, it acts on the mTORC1 protein and not on the
mTORC2 protein. As a consequence, the kinase AKT is hyper-
activated via an inhibition on the mTORC1-negative feedback
loop, while not inhibiting the mTORC2-positive feedback
loop. As TKIs it is orally delivered. It was studied in a multi-
center trial (RADIANT-3) in comparison with placebo. The
PFS was 11.0 months for everolimus versus 4.6 months for
placebo (p < 0.001). Furthermore, this outcome was confirmed
as independent from prior chemotherapy or somatostatin ana-
log in a subgroup analysis. The most frequent adverse effects
from everolimus were stomatitis, hyperglycemia and
pneumonitis [46–48].
The development of new targeted drugs
As reported here in GI tumors many targeted drugs are
approved and available in clinical practice as monotherapy
or combination with standard chemotherapy regimens. These
agents target various components of VEGF/VEGFR and
EGFR/HER2 pathways. Many studies are ongoing to
improve the efficacy of treatment targeting these pathways
and their downstream effectors. In the meanwhile, other sig-
naling pathways are explored to find a role in carcinogenesis
and cancer progression and potentially to discover new
antitumor agents (TABLE 2).
The improvement of previous treatments
Both bevacizumab and cetuximab/panitumumab were tested
in combination with other targeted agents for the treatment
of refractory mCRC in Phase II trials. Bevacizumab plus
everolimus combination was shown to be well tolerated in
patients previously treated with bevacizumab in a single-arm
Phase II trial. No complete or partial responses were seen.
The median PFS interval was 2.3 months, 26% of patients
achieved prolonged SD for ‡6 months and 6% were on study
for >1 year. However, some concerns are related to mucosal
damage and/or wound healing. Bevacizumab plus everolimus
appears to have modest activity in refractory mCRC in
patients [49]. Since preclinical studies [50] showed a synergistic
activity of cetuximab and erlotinib on growth inhibition in
colon cancer cell lines, a Phase II trial was performed to test
this combination. Response rate (RR) was 41% (95% CI:
26–57%) in KRAS-wild-type tumors, with a median PFS of
5.6 months (95% CI: 2.9–5.6 months). There was no
response in 11 patients with KRAS mutations. Frequent
grade 3 and 4 toxicities were rash (48%), hypomagnesemia
(18%) and fatigue (10%) [51]. Some of these targeted agents
were investigated in combination with chemotherapy. In
Review Rolfo, Bronte, Sortino et al.
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particular, sunitinib was delivered in combination with FOL-
FIRI to mCRC Japanese patients in a single-arm Phase II
trial. Median PFS did not meet the planned 35% improve-
ment compared with FOLFIRI alone. It was associated with
a high incidence of grade 3/4 hematologic toxicity impacting
on dose intensity. Subsequently, a non-Japanese Phase III
trial showed that sunitinib plus FOLFIRI is not superior to
FOLFIRI alone with a worse toxicity profile [52]. Similarly,
sorafenib was combined with FOLFOX6 in a randomized
Phase IIb trial in comparison with FOLFOX6 alone for first-
line treatment in mCRC. This study did not find a PFS ben-
efit with the combination therapy. KRAS and BRAF status
did not change this result [53].
In refractory mCRC patients, tivozanib, an oral VEGFR-1,
-2, -3 inhibitor, was studied in combination with everolimus
in a Phase Ib/II trial. This combination was well tolerated,
achieving stable disease in 50% of patients. The most com-
mon grade 3/4 adverse events were thrombocytopenia and
hypophosphatemia [54].
Novel anti-angiogenic TKIs were compared with sorafenib
for first-line treatment of advanced HCC in several Phase III
trials. These include sunitinib and linifanib, which target
VEGFR and PDGFR, and brivanib, targeting also FGFR.
None of these novel anti-angiogenic TKIs has shown superior
efficacy to sorafenib [55–57].
Brivanib was also compared with placebo for HCC after
sorafenib failure in the BRISK-PS Phase III trial. It showed a
higher overall response rate (ORR) (11.5 vs 1.9%) and a longer
median TTP (4.3 vs 2.7 months; p = 0.0001), but did not sig-
nificantly improve OS (9.4 vs 8.2 months; p = 0.33) [58].
Anti-angiogenic agents were also combined with erlotinib for
HCC in the SEARCH Phase III trial. Sorafenib plus erlotinib
were compared with sorafenib plus placebo [59]. No improve-
ment in TTP and OS was found. Furthermore, in a Phase II
trial, temsirolimus, a mTOR inhibitor, plus bevacizumab
achieved an ORR of 30.7% with fair tolerability for patients in
whom sorafenib failed [60].
The EGFR pathway has also been investigated for gastric
and esophageal cancers. The SWOG 0127 study, a Phase II
trial, showed no responses in patients with unresectable or aGC
treated with erlotinib while those with GEJ cancers obtained a
RR of 9%. OS was 6.7 months for GEJ cancer patients versus
3.5 months for gastric once and also TTP was better for
GEJ cancers (3.0 vs 1.7 months) [61]. Erlotinib with modified-
FOLFOX6 chemotherapy has been studied for patients with
metastatic or advanced adenocarcinoma of the esophagus and
GEJ obtaining a RR of 55%, a median PFS of 5.5 months
and a mOS of 11.0 months [62]. The combination of another
TKI, gefitinib, with cisplatin and 5-fluorouracil chemotherapy
plus radiotherapy, led to an improvement of OS in the neoad-
juvant setting, even though not significant (p = 0.06) [63].
According to these data, we can assume that the different
responses to TKI of GEJ carcinomas compared with stomach
cancers may be related not only to anatomical differences or
risk factors, but also to the activation of different molecular
pathways and different expressions of EGF receptors. Lapatinib
is another TKI, which has been evaluated in Phase II studies
for the treatment of aGC. However, it achieved modest clinical
benefit [64,65]. In the Phase III LOGIC study, the combination
therapy of lapatinib with capecitabine and oxaliplatin in com-
parison with chemotherapy alone as first-line treatment for
HER2-positive patients didn’t meet the primary end point
(mOS 12.2 vs 10.5 months; HR: 0.91; 95% CI: 0.73–1.12;
p = 0.35). Pre-specified subgroup analyses showed significant
improvements in OS in Asian patients (HR: 0.68) and those
under 60 years (HR: 0.69) [66]. Data of the TYTAN trial have
been recently presented at the 2013 American Society of Clini-
cal Oncology GI symposium. In this Asiatic study, lapatinib
has been evaluated in combination with paclitaxel versus pacli-
taxel alone in pretreated HER2 amplified aGCs. OS improve-
ment was not statistically significant in the intention-to-treat
population (11.0 vs 8.9 months; HR: 0.84; p = 0.2088)
Table 2. New targeted agents in clinical
development in advanced gastrointestinal tumors.
Type of tumor Targets Drugs Ref.
Colorectal cancer mTOR Everolimus [49]
EGFR Erlotinib [51]
VEGFR, BRAF,
KIT, RET, PDGFR
Sunitinib [52]
Sorafenib [53]
VEGFR Tivozanib [54]
Gastric cancer HER2 Lapatinib [66,67]
EGFR Erlotinib [61,62]
Gefitinib [63]
Cetuximab [68–71]
Panitumumab [72]
VEGF Bevacizumab [73–75]
Ramucirumab [78,79]
c-MET Foretinib [86]
Rilotumumab [87,93]
Onartuzumab [88]
Hepatocellular
carcinoma
VEGFR, BRAF,
KIT, RET, PDGFR
Sunitinib
Linifanib
[55,56]
FGFR Brivanib [57,58]
EGFR Erlotinib [59]
mTOR Temsirolimus [60]
c-MET Foretinib [82]
Tivantinib [83]
Cabozantinib [84]
MEK Selumetinib [89,90]
IGF/IGFR Cixutumumab [91]
The role of targeted therapy for GI tumors Review
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while in the Chinese subgroup of HER2-positive patients, this
improvement was higher [67].
In many Phase II trials, the association of cetuximab with
chemotherapy has been shown to have some efficacy [68,69]
and based on the increase of RR in previous studies,
Richards et al. evaluated in a Phase II trial the combination
of cetuximab and chemotherapy with docetaxel plus oxali-
platin (DOCOX) versus chemotherapy alone in patients
affected with metastatic gastric and GEJ adenocarcinoma.
Primary end point (PFS) was not met and the addition of
cetuximab didn’t improve either PFS or OS. They obtained
a minimal improvement in ORR in the combination arm
(38 vs 26%; 95% CI) without a real clinical benefit and
with increased toxicity, dose reductions and delays. Although
the incidence of KRAS mutations in gastric cancer is really
low, patients in this trial were unselected for RAS status and
this may be a reason for the lack of efficacy and the high
toxicity rates [70]. According to the poor results of the previ-
ous studies, data from the EXPAND trial, a Phase III ran-
domized study, confirmed that to date the association of
cetuximab with chemotherapy for the treatment of aGC has
not provided clinical benefits and that standard chemother-
apy is still the backbone [71]. In the REAL3 trial, 553 patients
with advanced esophagogastric cancer were randomized to
receive chemotherapy (epirubicin, oxaliplatin and capecita-
bine) or reduced-dose chemotherapy plus panitumumab.
The addition of panitumumab provided a reduction of mOS
from 11.3 months (95% CI: 9.6–13.0) with standard che-
motherapy alone, to 8.8 months for the combination (95%
CI: 7.7–9.8) [72].
Data from various Phase II studies suggested that the use
of bevacizumab in association with chemotherapy is a prom-
ising combination for patients with advanced GC and
GEJ tumors with a range of objective response of 65–67%
and survival of 12.3–16.8 months, laying the basis for further
larger trials [73,74]. In fact, in the AVAGAST study, a multi-
centric randomized placebo controlled Phase III trial,
773 patients with advanced gastric or GEJ cancer have been
treated with cisplatin and capecitabine and randomized to
receive in addition bevacizumab or placebo. The mOS was
12.1 months in the bevacizumab arm versus 10.1 for placebo,
but this difference was not significant (HR: 0.87;
p = 0.1002) and the trial didn’t meet the primary end point.
Nonetheless, both median PFS (6.7 vs 5.3 months; HR:
0.80; p. 0037) and ORR (46.0 vs 37.4%; p. 0315) were sig-
nificantly improved with bevacizumab versus placebo [75]. In
a post hoc subgroup analysis, Shah et al. have also shown that
the addition of bevacizumab to chemotherapy in European
and American patients had significantly improved OS in
patients with diffuse disease (mOS 6.5 vs 9.9 months; HR:
0.68) and in a marginal way in those with distal disease
(mOS 9.0 vs 11.7 months; HR: 0.72). Combining the data
of the two subtypes of cancer, there was a significant reduc-
tion of the risk of death, while Asiatic patients with any
type of disease showed no significant benefit from the
combination of bevacizumab to chemotherapy [76]. In another
analysis of the AVAGAST trial by Van Cutsem et al., it has
been demonstrated that patients with high plasma VEGF-A
levels show a trend toward improved OS versus patients with
low VEGF-A levels. Patients with low baseline expression of
neuropilin-1 also showed a trend toward improved OS versus
patients with high neuropilin-1 expression. For both bio-
markers, subgroup analyses demonstrated significance only in
patients from non-Asian regions [77].
Ramucirumab is a fully human mAb directed against the
extracellular VEGF-binding domain of VEGFR-2. In the
REGARD study, a Phase III, randomized double-blind trial,
ramucirumab monotherapy plus best supportive care (BSC)
has been compared with BSC plus placebo as second-line
therapy for patients with aGC. The mOS was higher for
patients in the experimental arm (5.2 vs 3.8 months; HR:
0.776; p = 0.0473) such as PFS (2.1 vs 1.3 months; HR:
0.483; p < 0.0001) and the most frequent grade ‡3 adverse
effects were hypertension, anemia, abdominal pain, ascites
and fatigue. Efficacy and safety of ramucirumab shown in
this trial seem to be promising, although second-line chemo-
therapy showed a similar survival benefit over BSC [78].
Results of the RAINBOW trial, a randomized multicenter
double-blind, placebo-controlled trial, have been presented at
the 2014 American Society of Clinical Oncology GI sympo-
sium. Ramucirumab has been evaluated in combination with
paclitaxel compared with paxlitaxel plus BSC in 665 patients
with metastatic GEJ and gastric adenocarcinoma in second-
line treatment after a first-line therapy with platinum- and
fluoropyrimidine-containing combination therapy. The trial
met the primary end point obtaining an improvement in
mOS for the ramucirumab arm (9.63 vs 7.36 months; HR:
0.87; 95% CI: 0.678–0.962; p = 0.0169) and in PFS
(4.40 vs 2.86 months; HR: 0.635; 95% CI: 0.536–0.752;
p < 0.0001) with a higher ORR (28 vs 16%; p = 0.0001)
and an acceptable toxicity profile [79].
The finding of further pathways to target
The c-MET proto-oncogene encodes for a surface receptor
whose natural activating ligand is HGF [80]. Its activation is
involved in cell diffusion, invasion and provides protection
from apoptosis and stimulates angiogenesis [81]. First promis-
ing data of activity of foretinib, a multi-target c-MET TKI,
came from a Phase I/II trial in which it produced an ORR of
24%, with a median TTP of 4.2 months and mOS of
15.7 months for patients affected by advanced HCC as first-
line therapy [82]. Tivantinib is a non-ATP-competitive
c-MET inhibitor, which has been studied in patients with
HCC after failure of sorafenib therapy in a Phase II, random-
ized, placebo-controlled trial whose results indicated an
advantage in patients with tumors overexpressing c-MET in
terms of median TTP (2.7 vs 1.4 months; HR: 0.43;
p = 0.03) and mOS (7.2 vs 3.8 months; HR: 0.38;
p = 0.01) [83]. This new c-MET TKI is currently being evalu-
ated in a Phase III, placebo-controlled, randomized study for
Review Rolfo, Bronte, Sortino et al.
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patients with c-MET overexpressing HCCs after failure of
sorafenib; the study is still recruiting.
Another molecule under study is cabozantinib, a non-
selective TKI directed versus c-MET, VEGFR-2 and RET.
Cabozantinib showed promising results in patients with HCC,
despite the small number of patients enrolled in the Phase II
study conduced by Verslype et al. [84] c-MET overexpression
occurs also in almost 21% of gastric cancers and it seems to
represent a negative prognostic factor [85]. A Phase II trial eval-
uated the use of foretinib as monotherapy in patients with met-
astatic gastric cancer with poor responses [86]. This study shows
that single-agent foretinib lacks efficacy in unselected patients
with aGC and selection according to MET amplification would
be needed.
Rilotumumab is a fully humanized anti-HGF mAb, which
has been studied in a Phase II trial in combination with epiru-
bicin-cisplatin-capecitabine chemotherapy (ECX) for patients
with aGC. It showed a trend toward improved survival in
patients with MET overexpression and treated with the addi-
tion of rilotumumab to chemotherapy, whereas the addition
was unfavorable in those with low MET expression [87]. These
preliminary data gave the start to the Phase III trial RILO-
MET-1, which is still ongoing.
Onartuzumab is another anti-Met mAb and it is being stud-
ied in a Phase III trial [88] that will evaluate the efficacy and
safety of the drug in combination with mFOLFOX6 in
patients with metastatic HER2-negative and MET-positive ade-
nocarcinoma of the stomach or GEJ. MEK represents another
molecular target, which has been evaluated in various solid
tumors such as malignant melanoma and non-small-cell lung
cancer.
Selumetinib, a MEK inhibitor, in monotherapy or in combi-
nation with sorafenib for HCC patients, seems to have some
activity, but findings are still preliminary and need to be con-
firmed [89,90]. IGF and IGF-1R-targeted molecules have been
also evaluated in monotherapy or in combination with sorafe-
nib for patients with HCC, although their unfavorable toxicity
profiles is limiting the clinical development [91,92].
Expert commentary
Fifteen years ago, most metastatic GI tumors were difficult to
treat with systemic therapy and in general prognosis was poor.
Over the years, improvement was achieved with the introduc-
tion of newer cytotoxic agents such as irinotecan, oxaliplatin
and taxanes. Especially in mCRC, the gain in OS has been
substantial. The mOS increased from 6 to more than
20 months.
With better knowledge of tumor biology and the interac-
tion between tumor and environment, a new class called tar-
geted drugs was developed. The original idea for their use
was that focusing on a specific target would translate into
more efficacy and less toxicity (meaning a better therapeutic
index). The first targeted drug introduced in GI tumors was
an unexpected success. Imatinib in metastatic GI stromal
tumors completely changed the management of these tumors.
This was the first systemic therapy, which showed a sizeable
anti-tumor activity.
In other GI tumors, interest was mainly focused on the
‘growth’ and ‘vascular’ pathways. Ten years ago, we had the
introduction of bevacizumab in the treatment of mCRC.
Afterward, relevant anti-tumor activity was shown with the
use of cetuximab and panitumumab, both EGFR inhibitors.
Although the progress per new drug was small, the overall
benefit in OS was important. Besides the introduction of
these new drugs, we experienced the role of biomarkers in GI
tumors. First KRAS and more recently RAS testing influence
dramatically our treatment algorithm in mCRC. Later, both
small molecules and antibodies showed activity in other GI
tumors such as gastric, neuroendocrine tumors and HCC.
What brings the future?
• in most of the GI tumors still a medical need exists for new
drugs;
• the determination of the best positioning of targeted therapy
in the treatment algorithm;
• understanding the tumor biology must form the base for
combination treatment with targeted therapy;
• further personalization of treatment is necessary, based both
on tumor and patient characteristics.
Five-year view
In our opinion, the next 5 years will see the development of
many new therapeutic strategies in the landscape of medical
treatment of solid tumors, including those of the GI tract. In
particular, we are waiting for more concrete data about the
activity of the new molecules with tyrosine kinase inhibition
activity. Many of the new knowledge on biology of GI
tumors derives from retrospective analyses of studies con-
ducted in patients, which often were not rigorously selected.
New prospective studies are needed in this field to identify
new biomarkers and to better explain the role and prognostic
significance of those that we have discovered recently.
The identification of new targets will provide soon new ther-
apeutic strategies. Namely, c-MET, RET, MEK and IGF/
IGFR will represent both further molecules to target and pre-
dictive factors to test to tailor cancer treatment.
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Key issues
• The introduction of targeted therapies radically changed the approach of oncologists in the treatment of the cancers of the
gastrointestinal tract.
• The addition of anti-VEGF, bevacizumab and anti-EGFR, cetuximab/panitumumab, to chemotherapy, significantly improved the survival
rates of metastatic colorectal cancer patients.
• Both small molecules and antibodies showed activity in other gastrointestinal (GI) tumors, such as gastric, neuroendocrine tumors and
hepatocellular carcinoma and are already available for clinical use in everyday practice.
• We now have molecular markers, whose identification has become mandatory for proper treatment planning in oncology.
• First KRAS and more recently RAS testing influence dramatically our treatment algorithm in metastatic colorectal cancer.
• A great number of new targeted agents are actually under preclinical and clinical development (i.e., MET inhibitors, MEK inhibitors,
etc.). Furthermore, an antibody–drug conjugate, such as trastuzumab emtansine, is under preclinical investigation in HER2-positive
gastric cancer cell lines in vitro and in vivo.
• Some of these new drugs, which are under development, were studied to improve the effects of previous agents on targets whose
impairments have been already known to be related to cancer development and progression.
• Researchers worldwide are looking for further molecular pathways involved in GI tumors and a great number of new targeted agents
are actually under investigation.
• Nowadays, targeted therapy is part of daily life of patients and physicians who treat those patients with GI tumors, but much more
progress can be made.
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